Patented asset
SYG BIOTECH holds a patented asset related to its historical biosensing foundation.
SYG BIOTECH
More than 10 years of R&D dedicated to measuring biological interactions.
SYG BIOTECH develops proprietary biosensing technologies and collaborative discovery programs to turn targeted biological interactions into quantitative R&D data.
Our approach
From programmable biosensing to experimental decisions.
SYG technologies originate from more than 10 years of research and development around programmable biosensing, biological interaction characterization and signal generation.
SYGPeD™ is SYG BIOTECH’s current quantitative functional biosensing platform, with immune checkpoints as the primary application focus and multi-target validation of the architecture. SYGPeP™ extends this logic toward partner-based functional discovery programs.
A collaboration-oriented biotech
SYG BIOTECH works at the interface of technology R&D, experimental validation and academic, hospital and industry collaboration.
PhD. Yannick GANGWE
Chief Executive Officer
Innovation & intellectual property
A proprietary foundation complemented by experimental know-how.
Know-how
Assay design, control selection, module configuration, quantitative analysis and experimental documentation.
Continuous innovation
New applications and collaborative discovery programs are developed with a structured approach to evidence, collaboration and asset protection.